Tema Etfs LLC Makes New Investment in Amgen Inc. (NASDAQ:AMGN)

Tema Etfs LLC bought a new position in shares of Amgen Inc. (NASDAQ:AMGN - Free Report) in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 11,179 shares of the medical research company's stock, valued at approximately $2,914,000. Amgen comprises approximately 1.2% of Tema Etfs LLC's investment portfolio, making the stock its 27th largest position.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in AMGN. Centricity Wealth Management LLC bought a new position in shares of Amgen in the 4th quarter valued at $25,000. Ritter Daniher Financial Advisory LLC DE lifted its stake in shares of Amgen by 66.2% in the 4th quarter. Ritter Daniher Financial Advisory LLC DE now owns 128 shares of the medical research company's stock valued at $33,000 after acquiring an additional 51 shares during the last quarter. Synergy Investment Management LLC bought a new position in shares of Amgen in the 4th quarter valued at $34,000. Atala Financial Inc bought a new position in shares of Amgen in the 4th quarter valued at $34,000. Finally, Heck Capital Advisors LLC bought a new position in Amgen during the 4th quarter worth $36,000. 76.50% of the stock is currently owned by institutional investors.

Amgen Trading Up 0.3%

Shares of AMGN stock opened at $272.41 on Friday. The company's fifty day simple moving average is $291.00 and its two-hundred day simple moving average is $288.09. The company has a debt-to-equity ratio of 9.62, a current ratio of 1.26 and a quick ratio of 0.95. Amgen Inc. has a 1 year low of $253.30 and a 1 year high of $346.85. The stock has a market capitalization of $146.48 billion, a price-to-earnings ratio of 36.08, a PEG ratio of 2.63 and a beta of 0.51.

Amgen (NASDAQ:AMGN - Get Free Report) last released its quarterly earnings results on Thursday, May 1st. The medical research company reported $4.90 earnings per share for the quarter, topping the consensus estimate of $4.18 by $0.72. The firm had revenue of $8.15 billion for the quarter, compared to analysts' expectations of $8.05 billion. Amgen had a net margin of 12.24% and a return on equity of 176.32%. The business's quarterly revenue was up 9.4% on a year-over-year basis. During the same quarter in the prior year, the firm posted $3.96 earnings per share. As a group, analysts anticipate that Amgen Inc. will post 20.62 earnings per share for the current year.

Amgen Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, June 6th. Stockholders of record on Friday, May 16th will be issued a $2.38 dividend. The ex-dividend date of this dividend is Friday, May 16th. This represents a $9.52 annualized dividend and a dividend yield of 3.49%. Amgen's payout ratio is currently 86.86%.

Insider Transactions at Amgen

In other Amgen news, EVP David M. Reese sold 25,225 shares of the company's stock in a transaction dated Friday, February 21st. The shares were sold at an average price of $304.44, for a total transaction of $7,679,499.00. Following the completion of the sale, the executive vice president now directly owns 36,922 shares in the company, valued at $11,240,533.68. This represents a 40.59% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Insiders own 0.76% of the company's stock.

Analyst Upgrades and Downgrades

Several research analysts recently issued reports on the company. Johnson Rice set a $294.00 target price on Amgen in a research report on Wednesday, March 5th. Erste Group Bank lowered Amgen from a "strong-buy" rating to a "hold" rating in a research report on Thursday, May 8th. UBS Group reissued a "neutral" rating and issued a $315.00 price objective (down from $319.00) on shares of Amgen in a research report on Friday, May 2nd. StockNews.com upgraded Amgen from a "buy" rating to a "strong-buy" rating in a research note on Sunday. Finally, Wells Fargo & Company restated an "equal weight" rating on shares of Amgen in a research note on Wednesday, February 5th. Two analysts have rated the stock with a sell rating, eleven have assigned a hold rating, nine have assigned a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat, Amgen has a consensus rating of "Hold" and an average price target of $310.18.

Amgen Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.

Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen Inc. (NASDAQ:AMGN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.